Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is hematology. Through research, he and his colleagues have pioneered the use of high-dose cyclophosphamide therapy for the treatment of aplastic anemia and other autoimmune conditions. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Oncology Research and a member of the Johns Hopkins Kimmel Cancer Center. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. Dr. Brodsky's research interests include high-dose cyclophosphamide, aplastic anemia and paroxysmal nocturnal hemoglobinuria. He has been recognized with numerous honors. In 2013, he received the Clinical Research Achievement Award from the Clinical Research Forum for second most important clinical research paper in medicine. He was named a Clinical Research Scholar of the Leukemia and Lymphoma Society of America in 2000 and a fellow of the American College of Physicians in 2004. He is a member of the American Society of Hematology and the International Society of Experimental Hematology.

high-dose cyclophosphamide, aplastic anemia, paroxysmal nocturnal hemoglobinuria